Regeneron Pharmaceuticals (REGN)

$498.84 6.29 (1.25%)

18:33 EST REGN Stock Quote Delayed 30 Minutes

Volume:

Previous Close -

Market Cap 52.85B

PE Ratio 40.42

EPS 12.34

Volume (Avg. Vol.) 964,026

Day's Range 497.12 - 509.54

52-Week Range 328.13 - 664.64

Dividend & Yield N/A (N/A)

REGN Stock Predictions, Articles, and Regeneron Pharmaceuticals News

From InvestorPlace
From the Web

4 Pharmaceutical Stocks That Aren’t Worth Their Outsized 2020 Gains

By Joel Baglole Dec 1, 2020

Now that companies such as Pfizer, Moderna and AstraZeneca have emerged with viable vaccines against Covid-19, the hype around many pharmaceutical stocks is fading. Here are four stocks investors should be weary of in the weeks ahead.

Pfizer, Moderna Lead the Vaccine Race: Here’s Where 7 Other Top Vaccine Stocks Stand

By Josh Enomoto, InvestorPlace Contributor Nov 24, 2020

As Pfizer and Moderna take the lead in the novel coronavirus vaccine race, here’s how this affects other Covid-19-related biotech stocks.

REGN Stock: 11 Things for Investors to Know About Regeneron Approval

By Sarah Smith, InvestorPlace Web Content Producer Nov 23, 2020

REGN stock is shifting the market today thanks to news its coronavirus treatment received emergency FDA approval.

7 Pharmaceutical Stocks to Buy for 2021 and Beyond

By Bret Kenwell, InvestorPlace Contributor Nov 17, 2020

Pharmaceutical stocks help make the world go round. Without them, common ailments would plague our lives. With them, we can solve Covid-19.

4 Top Biotech Stocks to Buy for Operation Warp Speed

By Joel Baglole Nov 3, 2020

The U.S. government has pulled out all the stops to develop a treatment for Covid-19. These biotech stocks are leading the race for a cure.

7 Cutting-Edge Biotech Stocks for Tomorrow

By Bret Kenwell, InvestorPlace Contributor Oct 28, 2020

Biotech stocks are always going to be here, in good times and bad. Let's look at a few that are worth considering on the long side.

7 Highly Rated Pharmaceutical Stocks for Q4

By Joel Baglole Oct 12, 2020

Investors are banking on an upsurge in pharmaceutical stocks once various vaccines and other therapies gain commercial approval from the U.S. Food and Drug Administration (FDA). Here is a list of pharmaceutical companies that stand to benefit in the coming months.

REGN Stock: Regeneron Pops on Trump’s Antibody Support

By Sarah Smith, InvestorPlace Web Content Producer Oct 8, 2020

With Trump's support, Regeneron just filed for emergency-use authorization with the FDA. REGN stock is climbing on the news.

7 Biotech Stocks To Buy For Profit From The Vaccine Crunch

By Tezcan Gecgil, InvestorPlace Contributor Oct 7, 2020

As the race to develop a vaccine continues, these biotech stocks could be high risk, high return propositions.

4 Top Stock Trades for Tuesday: SQ, REGN, APHA, TLRY

By Bret Kenwell, InvestorPlace Contributor Oct 5, 2020

Square, Regeneron, Aphria and Tilray were our top stock trades for Tuesday. That said, here's how the charts look after Monday's action.

Regeneron Pharmaceuticals Stock Shoots Up 8% on Trump Treatment

By William White, InvestorPlace Writer Oct 5, 2020

Regeneron Pharmaceuticals (REGN) stock is soaring Monday on news that its treatment for the coronavirus was used on President Trump.

5 of the Best Pharmaceutical Stocks to Buy Right Now

By David Moadel, InvestorPlace Contributor Sep 10, 2020

A handful of pharmaceutical stocks have been on fire lately, but I'm writing for a "buy" prescription for five of the best names now.

4 Pharmaceutical Stocks With Deep Pipelines

By Larry Ramer, InvestorPlace Contributor Sep 2, 2020

Coronavirus vaccines get all the attention, but these four pharmaceutical stocks benefit from equipment, drug and test kit developments.

Regeneron Stock Is a Play For Covid-19, And More

By Dana Blankenhorn, InvestorPlace Contributor Aug 18, 2020

Regeneron is trialing a cocktail of antibodies that may treat Covid-19 and prevent illness for people routinely exposed.

Regeneron Stock Is a Solid Long-Term Buy

By Dana Blankenhorn, InvestorPlace Contributor May 27, 2020

Investors are excited about Regeneron stock for its Covid-19 treatment. They're missing the point. Regeneron is a great long-term buy.

3 Earnings Stocks to Buy While They Climb Above Everything Else

By Chris Tyler, InvestorPlace Contributor May 15, 2020

It may be time to continue selling in May, but not for these all-star earnings stocks to buy. Here's why each stands out from the crowd.

7 Beautiful Biotech Stocks to Buy Here

By Louis Navellier and the InvestorPlace Research Staff, Editor, Growth Investor Apr 24, 2020

Covid-19 has put the biotech stocks in the spotlight, but treatments for the pandemic are far from the only reason investors should watch this space.

10 S&P 500 Stocks That Are Still Overvalued By Discounted Cash Flow

By Will Ashworth, InvestorPlace Contributor Apr 21, 2020

Despite a year-to date drop of -13.9%, the S&P 500 could still be overpriced by 35%. If the S&P 500 is overvalued, component stocks must be.

7 of the Best Large-Cap Stocks to Buy Now

By Louis Navellier and the InvestorPlace Research Staff, Editor, Growth Investor Apr 21, 2020

In times like this, investors are better off focusing on large-cap stocks that offer size, capital and products the economy truly relies on.

Three Reasons to Consider Buying Regeneron Stock

By Bret Kenwell, InvestorPlace Contributor Apr 14, 2020

Regeneron has solid cash flow and a strong balance sheet. Oh and Regeneron stock is flirting with a major breakout.

Red-Hot Biotechs to Take Center Stage at Blood Disorder Meeting

From Bloomberg Dec 3, 2020

High-flying drug developers that have surged in the face of the ongoing coronavirus pandemic will be in focus starting this weekend at the year’s last big medical meeting, putting surging stocks under the microscope for investors who have cheered massive gains.

Navellier Ratings

Total Grade

Buy

Regeneron Pharmaceuticals (REGN)

REGN Stock Predictions, Articles, and Regeneron Pharmaceuticals News

Navellier Ratings

Total Grade

Subscriber Sign in